TrialQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2023

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.

Laurie E McLouth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.